Search

Controlled release has traditionally been conceptualised as a pharmaceutical formulation strategy for modifying drug input into the body. Within this view, long-acting injections, implants, transdermal systems, microneedle platforms, depot formulations, and extended-release systems are primarily evaluated through release kinetics, bioavailability, dose reduction, and pharmacokinetic smoothing. This article proposes a broader systems theory interpretation: controlled release technologies should be understood as temporal therapeutic infrastructure. Rather than acting merely as dosage forms, long-acting pharmaceutical technologies organise therapeutic time by distributing drug exposure across days, weeks, or months; reducing dependence on repeated patient action; buffering behavioural variability; and maintaining pharmacological continuity across clinical and everyday contexts. The article develops an original theoretical framework that links controlled release design to infrastructure logic, systems thinking, patient behaviour alignment, and therapeutic continuity. It argues that long-acting technologies create a temporal architecture within which patients, clinicians, drug products, appointments, monitoring systems, and disease dynamics interact. This reframing shifts evaluation away from isolated product performance and toward system-level questions: how much temporal flexibility a technology provides, how it absorbs missed doses or delayed visits, how it prevents sub-therapeutic gaps or accumulation, and how it redistributes responsibility between patient behaviour and pharmaceutical design. The framework contributes a systems-oriented vocabulary for analysing controlled release technologies as infrastructures of continuity, adherence, and time-sensitive therapeutic governance.